3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Melanoma
9
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Multiple Myeloma
1
Microsatellite Instability
1
Melanoma, Cutaneous Malignant
1
Interventions
Carboplatin
121
pembrolizumab
119
Pemetrexed
102
Cisplatin
76
Paclitaxel
56
osimertinib
52
Nivolumab
50
Docetaxel
50
durvalumab
47
Specimen Handling
37
Gemcitabine
34
Magnetic Resonance Spectroscopy
33
Radiosurgery
27
Cetuximab
26
130-nm albumin-bound paclitaxel
26
atezolizumab
25
Radiotherapy
20
Ipilimumab
19
Drug Therapy
19
Bevacizumab
19
cemiplimab
17
amivantamab
17
Taxes
16
Ramucirumab
13
alectinib
12
tislelizumab
11
lazertinib
11
Leucovorin
11
Fluorouracil
11
Radiation
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
relatlimab
×
90 days
×
Clear all
NCT05176483
2026-05-27
STELLAR-002
Exelixis
Phase 1
Recruiting
1,314 enrolled
NCT06561386
2026-05-20
RELATIVITY1093
Bristol-Myers Squibb
Phase 3
Recruiting
1,000 enrolled